Medical Condition News

RSS

Surgery may not be the best option for children with obstructive sleep apnea

For children with obstructive sleep apnea, standard care often includes a tonsillectomy and adenoidectomy. But researchers at Saint Louis University say further research is needed to determine if surgery is the best option for these patients.

5 Nov 2009

Green tea extract shows promise as cancer prevention agent for oral cancer, reveal researchers

Green tea extract has shown promise as cancer prevention agent for oral cancer in patients with a pre-malignant condition known as oral leukoplakia, according to researchers at The University of Texas M. D. Anderson Cancer Center.

5 Nov 2009

People with MS who relapse within first five years of onset have more severe disability: Study

People with multiple sclerosis (MS) who have relapses within the first five years of onset appear to have more severe disability in the short term compared to people who do not have an early relapse, according to a new study published in the November 4, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology. The study is one of the first to examine how MS relapses affect people during different time periods of the disease.

5 Nov 2009

Adolescents with chronic health conditions rely more on Internet

The Internet has become a popular socializing tool for adolescents and a new study shows those with chronic health conditions might rely on it more heavily than their peers do.

5 Nov 2009

Echo Therapeutics commences its Symphony Transdermal Continuous Glucose Monitoring System clinical study

Echo Therapeutics, Inc., a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery announced today that it has initiated a clinical study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System (tCGM System) in patients with Type 1 and Type 2 diabetes.

5 Nov 2009

Cook Medical and AOPA partner to offer AAA screenings at AOPA Aviation Summit

Cook Medical is partnering with the Aircraft Owners and Pilots Association (AOPA) at this year’s AOPA Aviation Summit in Tampa, Fla. from November 5-7 to provide free abdominal aortic aneurysm (AAA) screenings to its attendees at high risk for AAA.

5 Nov 2009

EFOF's initative to raise epilepsy awareness

Each year, some 50,000 Americans die from seizures and related causes, triggering more deaths annually than breast cancer. The Epilepsy Foundation of Florida (EFOF) is working to educate the public about this condition during November, Epilepsy Awareness Month.

4 Nov 2009

Designers of anti-cancer drugs aim at the genetic material DNA in preventing cancer cells

Designers of anti-cancer drugs are aiming their arrows at mysterious chunks of the genetic material DNA that may play a key role in preventing the growth and spread of cancer cells, according to an article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.

4 Nov 2009

Cancer patients want strong relationship with their radiation oncologist

What do patients want from their radiation oncologists? The most significant preference is that more than one-third of female cancer patients (37 percent) prefer to have their hands held by their radiation oncologists during important office visits, compared to 12 percent of men, according to a randomized study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

4 Nov 2009

Marianjoy Rehabilitation Hospital offers behavioral testing for children

Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.

4 Nov 2009

"Alternate-day fasting" reduces body weight and improves cardio health: Study

Restricting daily calorie intake is a common plan to help obese and overweight people slim down to healthier weights. But the regime requires a daily 15 to 40 percent calorie reduction, which makes sticking to the diet hard for many.

4 Nov 2009

Statins may have negative effects on some cardiac patients, says study

Although statins are widely used to prevent heart attacks, strokes, and other cardiovascular disorders, new research shows that the class of drugs may actually have negative effects on some cardiac patients. A new study presented at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP), found that statins have beneficial effects on patients with systolic heart failure (SHF), but those with diastolic heart failure (DHF) experienced the opposite effect, including increased dyspnea, fatigue, and decreased exercise tolerance.

4 Nov 2009

Possible cure for Parkinson's disease

Researchers at Iowa State University have found an essential key to possibly cure Parkinson's disease and are looking for others.

4 Nov 2009

GenVec receives FDA orphan drug designation for TNFerade

GenVec, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TNFerade(TM) for the treatment of pancreatic cancer.

4 Nov 2009

Gastric cancer drug market to double to nearly $1.5 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the gastric cancer drug market -- driven by the launch of several targeted agents over the next few years -- will more than double from approximately $700 million in 2008 to nearly $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

4 Nov 2009

Acceleron Pharma commences Phase 1 clinical study of its novel angiogenesis inhibitor

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor.

4 Nov 2009

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free survival, according to data presented on Tuesday, November 3, 2009 at the 51st American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Chicago, Illinois.

4 Nov 2009

PAH patients face life-threatening risks from medication errors

Pulmonary arterial hypertension (PAH) patients using infused drugs have suffered serious injury or in some cases died from medication errors in hospitals and other inpatient settings, according to a peer-reviewed study by Accredo Health Group and several university hospitals that surveyed doctors, nurses and pharmacists.

4 Nov 2009

Shionogi files New Drug Application in Japan

BioCryst Pharmaceuticals, Inc. today announced that its partner, Shionogi & Co., Ltd. has filed a New Drug Application (NDA) in Japan to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza. As a consequence of this filing, BioCryst will receive a regulatory milestone payment of $7 million under its agreement with Shionogi.

4 Nov 2009

Shire receives FDA Priority Review for velaglucerase alfa NDA

Shire plc, the global specialty biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.

4 Nov 2009